Connect with us

Hi, what are you looking for?


AstraZeneca withdraws clinical trials

British drugmaker AstraZeneca has withdrawn its application for clinical trials of its coronavirus vaccine in the country, according to the chief of the local Food and Drug Administration (FDA).

The vaccine developer was withdrawing because “they have enough data already,” FDA Director-General Rolando Enrique D. Domingo said in a text message.

AstraZeneca was among the three clinical trial applicants approved by the ethics review board of the Science and Technology department.

The private sector, government and AstraZeneca have signed a deal for the purchase of 2.6 million doses of vaccines.

Joey A. Concepcion, presidential adviser for entrepreneurship, told an online briefing last month that half of the vaccines would be given to the private sector and the other half will be donated to the government.

The vaccines are expected to arrive in May or June next year, he said.

Four other vaccine makers are applying for clinical trials in the country.

Meanwhile, Janssen Pharmaceutical Companies of Johnson & Johnson and Chinese drug company Clover Biopharmaceuticals have been approved by both the expert panel and ethics committee and would now go through the FDA process, Health Undersecretary Maria Rosario S. Vergeire told an online news briefing on Friday.

China’s Sinovac Biotech Ltd., the first to get approval from the expert panel, and Russia’s Gamaleya Research Institute of Epidemiology and Microbiology are also applying for clinical trials in the country.

The Department of Health (DoH) reported 1,504 coronavirus infections on Friday, bringing the total to 447,039.
The death toll rose to 8,709 after eight more patients died, while recoveries increased by 273 to 409,329, it said in a bulletin.

There were 29,001 active cases, 85.8% of which were mild, 6.7% did not show symptoms, 4.8% were critical, 2.4% were severe and 0.25% were moderate.

Davao City reported the highest number of new cases at 122, followed by Rizal at 85, Quezon City at 80, Santiago City at 67 and Bulacan at 64.

DoH said five duplicates had been removed from the tally, while one recovered patient was reclassified as death. Twelve laboratories failed to submit their data on Dec. 10, it said. — Vann Marlo M. Villegas

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!



WASHINGTON D.C. — The United States is seeking to form a coalition of countries to drive negotiations on a global plastic pollution treaty, weeks...


By Diego Gabriel C. Robles  THE WORLD BANK (WB) upgraded its growth forecast for the Philippines for this year and 2023, citing an “accommodative”...


THE PHILIPPINE auto industry’s sales recovery will likely be derailed if a measure reimposing excise taxes on pickup trucks is signed into law, according...


THE BANGKO SENTRAL ng Pilipinas (BSP) may deliver a second off-cycle rate hike in early November when the US Federal Reserve is expected to...


THE ASIAN Development Bank (ADB) is planning to allocate at least $14 billion for a program aimed at easing a food crisis in the...


With the reversal of the 1.25% rise in National Insurance Contributions happening on the 6th of November, employers across the nation have an opportunity...

You May Also Like


Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...


The minute that any question pops into your head, you can simply ask Google. No longer do we have to pour over books and...


Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...


Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.